ChiCTR2200063952 版本V1.0 版本创建时间2022/09/21 18:11:36 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2200063952 

最近更新日期:

Date of Last Refreshed on:

2022-09-21 18:11:26 

注册时间:

Date of Registration:

2022-09-21 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

丙泊酚与依托咪酯用于冠脉搭桥手术麻醉诱导对患者心脏功能的影响

Public title:

Effect of Etomidate vs Propofol on cardiac function for Induction in Coronary Artery Bypass Grafting

注册题目简写:

English Acronym:

研究课题的正式科学名称:

丙泊酚与依托咪酯用于冠脉搭桥手术麻醉诱导对患者心脏功能的影响

Scientific title:

Effect of Etomidate vs Propofol on cardiac function for Induction in Coronary Artery Bypass Grafting

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

詹明盈 

研究负责人:

陈宇 

Applicant:

Mingying Zhan 

Study leader:

Yu Chen 

申请注册联系人电话:

Applicant telephone:

008618520394509

研究负责人电话:

Study leader's
telephone:

008613631453324

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

zhanmy5@mail2.sysu.edu.cn

研究负责人电子邮件:

Study leader's E-mail:

chen@mail.sysu.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

广州市越秀区中山二路58号,中山大学附属第一医院,麻醉科

研究负责人通讯地址:

广州市越秀区中山二路58号,中山大学附属第一医院,麻醉科

Applicant address:

Department of Anesthesiology, First Affiliated Hospital, Sun Yat-sen University, 58 Zhongshan 2 Rd, Guangzhou, China.

Study leader's address:

Department of Anesthesiology, First Affiliated Hospital, Sun Yat-sen University, 58 Zhongshan 2 Rd, Guangzhou, China.

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

中山大学附属第一医院

Applicant's institution:

The First Affiliated Hospital,Sun Yat-sen University

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

伦审[2021]733-1

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中山大学附属第一医院临床科研和实验动物伦理委员会

Name of the ethic committee:

IEC for Clinical Research and Animal trials of the First Affiliated Hospital of Sun Yat-Sen University

伦理委员会批准日期:

Date of approved by ethic committee:

2021-12-23 00:00:00

伦理委员会联系人:

颜楚荣

Contact Name of the ethic committee:

Churong, Yan

伦理委员会联系地址:

广州市越秀区中山二路58号,中山大学附属第一医院

Contact Address of the ethic committee:

First Affiliated Hospital, Sun Yat-sen University, 58 Zhongshan 2 Rd, Guangzhou, China.

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

中山大学附属第一医院

Primary sponsor:

The First Affiliated Hospital,Sun Yat-sen University

研究实施负责(组长)单位地址:

广州市越秀区中山二路58号,中山大学附属第一医院

Primary sponsor's address:

First Affiliated Hospital, Sun Yat-sen University, 58 Zhongshan 2 Rd, Guangzhou, China.

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东

市(区县):

广州

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

中山大学附属第一医院

具体地址:

越秀区中山二路58号

Institution
hospital:

The First Affiliated Hospital, Sun Yat-sen University

Address:

58 Second Zhongshan Road, Yuexiu District

经费或物资来源:

本单位

Source(s) of funding:

Hospital

研究疾病:

冠心病  

Target disease:

coronary heart disease

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

探究丙泊酚与依托咪酯用于冠脉搭桥手术麻醉诱导对患者左室长轴应变及其他心脏功能指标的影响。  

Objectives of Study:

To explore the effects of propofol and etomidate on global longitudinal strain and other cardiac function indexes in patients undergoing coronary artery bypass grafting.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1. 年龄≥18岁
2. 行择期冠脉搭桥手术
3. 签署知情同意书

Inclusion criteria

1. Aged≥18 years old
2. Undergoing elective CABG surgery
3. Sign informed consent

排除标准:

1. 术前需IABP或ECMO辅助循环
2. 合并中度以上瓣膜病变或心内膜炎
3. 合并其他心脏手术:瓣膜手术及主动脉置换手术
4. 既往心脏手术:需要打开心包的大型心脏手术
5. 严重心律失常:快速型房颤、房扑、室速、室颤、Ⅱ度和Ⅲ度房室传导阻滞等
6. 困难气道
7. 对丙泊酚、依托咪酯、舒芬太尼、顺式阿曲库铵过敏酚、依托咪酯、舒芬太尼、顺式阿曲库铵过敏

Exclusion criteria:

1. Need IABP or ECMO to assist circulation before surgery
2. Moderate or severe valvular disease, endocarditis
3. Combined with other cardiac surgery:valve repair surgery, replacement of part of the aorta
4. Previous cardiac surgery: major cardiac surgery requiring opening of the pericardium.
5. Serious arrhythmia:rapid atrial fibrillation, atrial flutter, ventricular tachycardia, ventricular fibrillation, second degree and third degree Atrioventricular Block, etc
6. Difficult airway
7. Allergy to propofol,etomidate,sufentanil or Cis-atracurium

研究实施时间:

Study execute time:

From 2022-09-21 00:00:00 To 2022-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2022-09-21 00:00:00 To 2022-12-31 00:00:00

干预措施:

Interventions:

组别:

P组

样本量:

54

Group:

Group P

Sample size:

干预措施:

使用丙泊酚诱导

干预措施代码:

Intervention:

use propofol for induction

Intervention code:

组别:

E组

样本量:

54

Group:

Group E

Sample size:

干预措施:

使用依托咪酯诱导

干预措施代码:

Intervention:

use etomidate for induction

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广东 

市(区县):

广州 

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

中山大学附属第一医院 

单位级别:

三甲 

Institution
hospital:

The First Affiliated Hospital, Sun Yat-sen University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

诱导后患者左室总体长轴应变相比诱导前的变化率

指标类型:

主要指标

Outcome:

The relative change rate of left ventricle global longitudinal strain after induction compared with that before induction

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

诱导后患者左室长轴总体应变相比诱导前的变化量

指标类型:

次要指标

Outcome:

The absolute change of left ventricle global longitudinal strain after induction compared with that before induction

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

诱导后患者相比诱导前左室长轴总体应变变化率大于10%的发生率

指标类型:

次要指标

Outcome:

Incidence of the relative change rate of left ventricle global longitudinal strain after induction compared with that before induction greater than 10%

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

左室射血分数

指标类型:

次要指标

Outcome:

Left ventricular ejection fraction

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

二尖瓣E/A比值

指标类型:

次要指标

Outcome:

Mitral E/A ratios

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

二尖瓣侧壁与室间隔E/e’值

指标类型:

次要指标

Outcome:

The septal and lateral mitral E/e' ratios

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

二尖瓣E峰减速时间

指标类型:

次要指标

Outcome:

Mitral E wave deceleration time

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

三尖瓣环收缩期位移

指标类型:

次要指标

Outcome:

Tricuspid annular plane systolic excursion

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

校正血流时间

指标类型:

次要指标

Outcome:

Corrected flow time

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

左室收缩末容积

指标类型:

次要指标

Outcome:

Left ventricular end-systolic volume

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

左室舒张末容积

指标类型:

次要指标

Outcome:

Left ventricular end-diastolic volume

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

每搏输出量

指标类型:

次要指标

Outcome:

Stroke volume

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

每博输出指数

指标类型:

次要指标

Outcome:

Stroke volume index

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

心率

指标类型:

次要指标

Outcome:

Heart rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

心输出量

指标类型:

次要指标

Outcome:

Cardiac output

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

心脏指数

指标类型:

次要指标

Outcome:

Cardiac index

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

诱导期低血压发生率

指标类型:

次要指标

Outcome:

Incidence of hypotension during induction

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

Null

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

实验开始前使用SPSS软件生成随机数字,并生成随机分组表,术前1天由特定研究人员根据入排标准纳入患者,并根据入组时间进入随机分组表的不同组别

Randomization Procedure (please state who generates the random number sequence and by what method):

Before the start of the experiment, use SPSS software to generate random numbers and generate a random grouping table. One day before the operation, a specific researcher will enroll patients according to the inclusion criteria, and enter the different groups of the random grouping table in chronological order.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

试验和统计完成后,上传原始数据记录表

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Upload the original data record sheet after the trial complete

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

用病历记录表记录数据,并录入excel电子版

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Record the data in the medical record form and input the excel electronic vers

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2022-09-21 18:11:26